Approved for To treat locally advanced or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations after systemic therapy. 12.1 Mechanism of Action Sevabertinib is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). It also exhibits activity against epidermal growth factor receptor (EGFR).… Side effects, costs, interactions, manufacturer,…
Loading full data from Know Your Drugs Institute…